BRUKINSA Achieves Landmark 74% Six-Year Progression-Free Survival in Treatment-Naïve Chronic Lymphocytic Leukemia Patients
BRUKINSA Achieves Landmark 74% Six-Year Progression-Free Survival in Treatment-Naïve Chronic Lymphocytic Leukemia Patients BeOne Medicines Ltd., a global oncology company, reaffirms its position as the leader in chronic lymphocytic leukemia…
Bristol Myers Squibb Showcases New Data in Targeted Protein Degradation and Cell Therapy for Lymphoma at ASH 2025
Bristol Myers Squibb reinforces its hematology leadership through new research across multiple therapies for patients with lymphoma at the 67th American Society of Hematology (ASH) Annual Meeting. Highlights include updates…
Roche Shows Lunsumio’s Potential in Earlier Lymphoma Lines
Roche Highlights Lunsumio Data Demonstrating Promise in Earlier Treatment Settings for Both Indolent and Aggressive Lymphomas Roche announced today new data highlighting the potential of Lunsumio® (mosunetuzumab) in earlier treatment…
Blueprint Medicines Highlights Long-Term AYVAKIT® Benefits in Systemic Mastocytosis at ASH 2025
Blueprint Medicines presents long-term AYVAKIT® benefits in indolent and advanced systemic mastocytosis at ASH 2025. Blueprint Medicines, a Sanofi company, today announced updated data reinforcing the clinical efficacy and safety of…
Johnson & Johnson’s INLEXZO™ (Gemcitabine Intravesical System) Achieves 74% Disease-Free Survival at One Year in BCG-Unresponsive, High-Risk, Papillary-Only NMIBC
Johnson & Johnson’s INLEXZO™ (Gemcitabine Intravesical System) Achieves 74% Disease-Free Survival at One Year in Patients with BCG-Unresponsive, High-Risk, Papillary-Only NMIBC Johnson & Johnson announced today that new data from…
Most Countries Advance on Universal Health Coverage, but Challenges Persist – WHO/World Bank
Most Nations Advance Toward Universal Health Coverage, Yet Significant Obstacles Persist, Finds WHO–World Bank Report Since 2000, most countries – across all income levels and regions – have made concurrent…
Biogen and Stoke Present Promising Zorevunersen Data for Dravet Syndrome at AES 2025
Biogen and Stoke Present New Data Supporting Zorevunersen’s Disease-Modifying Potential in Dravet Syndrome at AES 2025 Biogen and Stoke Therapeutics, a biotechnology company dedicated to restoring protein expression by harnessing the…
Zoetis Secures Health Canada Approval for Portela™ (relfovetmab Injection) to Relieve Osteoarthritis Pain in Cats
Zoetis Secures Health Canada Approval for Portela™ (relfovetmab Injection) to Relieve Osteoarthritis Pain in Cats Zoetis Inc. today announced that Health Canada has approved Portela™ (relfovetmab injection) for the alleviation of pain…
Ossium Health to Unveil New Clinical Data on Organ Donor-Derived Bone Marrow at ASH 2025
Advancing Transplant Innovation with First-of-Its-Kind Insights from Organ Donor-Derived Bone Marrow Ossium Health, a bioengineering company that developed a first-of-its-kind bank of bone marrow available on-demand, will present new clinical…
IDE034, a Bispecific Antibody-Drug Conjugate Licensed by Biocytogen to IDEAYA, Receives FDA IND Clearance
IDE034, a Bispecific Antibody-Drug Conjugate Licensed by Biocytogen to IDEAYA, Secures FDA IND Clearance Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, HKEX: 02315), announced that its partner IDEAYA Biosciences, Inc. (Nasdaq:…
Egypt Attains Self-Sufficiency in Plasma-Derived Medicines with Support from Grifols
Egypt Achieves Historic Milestone in Healthcare Sovereignty: Becomes Sixth Nation to Attain Plasma Self-Sufficiency with Grifols Partnership Plasma-derived medicines—a feat made possible through a groundbreaking five-year strategic alliance with Grifols,…
MediaBayer Launches Phase IIa Clinical Trial for Alport Syndrome Therapy
Bayer Launches Phase IIa Clinical Trial of Novel Therapy for Alport Syndrome Bayer has announced the initiation of a Phase IIa clinical trial evaluating BAY 3401016, an investigational monoclonal antibody…